A Phase III Double-blind, Randomized, Parallel Group, Multicenter Placebo-controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

Trial Profile

A Phase III Double-blind, Randomized, Parallel Group, Multicenter Placebo-controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Caplacizumab (Primary) ; Caplacizumab (Primary)
  • Indications Thrombotic thrombocytopenic purpura
  • Focus Registrational; Therapeutic Use
  • Acronyms HERCULES
  • Sponsors Ablynx
  • Most Recent Events

    • 12 Dec 2017 According to an Ablynx media release, data from the study has been presented at the 59th Annual Meeting of the American Society of Hematology (ASH).
    • 12 Dec 2017 Results published in an Ablynx media release.
    • 21 Nov 2017 According to an Ablynx media release, data will be presented at the 59th Annual Meeting of the American Society of Hematology (ASH).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top